FDA to Launch Priority Vouchers for Companies Supporting U.S. Interests

The FDA announced a new Commissioner’s National Priority Voucher program to expedite drug reviews for companies aligned with U.S. health priorities, reducing review times from 10-12 months to 1-2 months through a team-based, multidisciplinary review process, aiming to bring more cures and treatments to Americans efficiently while maintaining safety standards.